Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 15 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.46 Insider Own3.09% Shs Outstand191.38M Perf Week19.85%
Market Cap288.28M Forward P/E- EPS next Y-0.71 Insider Trans-1.28% Shs Float177.94M Perf Month82.56%
Income-276.06M PEG- EPS next Q-0.19 Inst Own65.28% Short Float1.33% Perf Quarter193.90%
Sales90.12M P/S3.20 EPS this Y38.97% Inst Trans-4.28% Short Ratio1.03 Perf Half Y200.59%
Book/sh0.68 P/B2.29 EPS next Y19.49% ROA-49.80% Short Interest2.36M Perf Year52.43%
Cash/sh1.65 P/C0.95 EPS next 5Y-7.30% ROE-110.95% 52W Range0.41 - 1.75 Perf YTD177.88%
Dividend Est.- P/FCF- EPS past 5Y- ROI-80.69% 52W High-10.29% Beta0.73
Dividend TTM- Quick Ratio6.14 Sales past 5Y-20.42% Gross Margin62.53% 52W Low280.51% ATR (14)0.15
Dividend Ex-Date- Current Ratio6.45 EPS Y/Y TTM26.08% Oper. Margin-150.05% RSI (14)75.52 Volatility16.62% 11.31%
Employees137 Debt/Eq1.76 Sales Y/Y TTM-2.10% Profit Margin-306.31% Recom3.00 Target Price3.00
Option/ShortYes / Yes LT Debt/Eq1.61 EPS Q/Q30.53% Payout- Rel Volume1.24 Prev Close1.67
Sales Surprise11.47% EPS Surprise-4.56% Sales Q/Q8.45% EarningsMar 04 AMC Avg Volume2.30M Price1.57
SMA2045.84% SMA5078.91% SMA200143.10% Trades Volume2,846,826 Change-5.99%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Underweight
Nov-09-23Upgrade TD Cowen Market Perform → Outperform
May-10-23Upgrade Jefferies Underperform → Hold $1.50 → $1
Feb-24-23Downgrade Jefferies Hold → Underperform $3.20 → $1.50
Aug-08-22Downgrade JP Morgan Neutral → Underweight
May-31-22Resumed Jefferies Hold $12 → $4
Apr-18-22Downgrade Goldman Neutral → Sell $3
Mar-15-22Downgrade Mizuho Buy → Neutral $35 → $8
Mar-15-22Downgrade Cowen Outperform → Market Perform
Mar-14-22Downgrade William Blair Outperform → Mkt Perform
Apr-03-24 11:30AM
Mar-25-24 10:00AM
Mar-22-24 02:00PM
Mar-06-24 12:33PM
Mar-05-24 10:07AM
09:13AM Loading…
Mar-04-24 05:30PM
Feb-27-24 06:00PM
Feb-26-24 06:00PM
10:00AM Loading…
Feb-20-24 10:00AM
Jan-03-24 06:00PM
Dec-11-23 06:00PM
Dec-07-23 11:31AM
Nov-09-23 08:39AM
Nov-08-23 11:47AM
Nov-07-23 05:28PM
Oct-31-23 06:00PM
Oct-26-23 10:02AM
Oct-23-23 10:08AM
Oct-13-23 08:30AM
Oct-02-23 09:00AM
Sep-27-23 09:00AM
Sep-14-23 07:54AM
09:00AM Loading…
Sep-13-23 09:00AM
Sep-07-23 11:31AM
Sep-06-23 06:00PM
Aug-17-23 07:02PM
Aug-09-23 09:25AM
Aug-08-23 05:30PM
Aug-07-23 10:23AM
Aug-01-23 06:00PM
Jul-24-23 03:48AM
Jul-16-23 08:49AM
Jun-12-23 06:00PM
Jun-08-23 12:55PM
May-10-23 11:28AM
May-09-23 06:45PM
May-08-23 09:29AM
May-04-23 10:00AM
May-02-23 10:01AM
Apr-27-23 08:30AM
Apr-19-23 08:38AM
Apr-17-23 05:00PM
Apr-16-23 06:30AM
Apr-13-23 10:59AM
Apr-11-23 08:57AM
Apr-10-23 10:07AM
Apr-02-23 08:27AM
Mar-30-23 11:30AM
Mar-29-23 05:44PM
Mar-24-23 12:00PM
Mar-22-23 09:35AM
Mar-14-23 03:43AM
Feb-28-23 05:15PM
Feb-24-23 10:23AM
Feb-23-23 06:20PM
Jan-09-23 09:04AM
Jan-04-23 09:00AM
Dec-12-22 10:05AM
Dec-05-22 08:00AM
Nov-10-22 09:05AM
Nov-09-22 09:00AM
Nov-04-22 12:35PM
Nov-03-22 06:35PM
Oct-28-22 10:00AM
Oct-27-22 10:02AM
Oct-25-22 06:00PM
Oct-24-22 07:55AM
Oct-11-22 05:13PM
Oct-07-22 03:42PM
Sep-07-22 01:15AM
Aug-21-22 09:57AM
Aug-16-22 08:30AM
Aug-05-22 12:11PM
Aug-04-22 06:15PM
Jul-26-22 06:00PM
Jul-14-22 06:01AM
Jul-01-22 06:30AM
May-27-22 08:00AM
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBIN HOWARD WPresident & CEOFeb 20 '24Sale0.6820,03313,622879,889Feb 22 08:16 PM
Zalevsky JonathanChief R&D OfficerFeb 20 '24Sale0.689,0146,130265,025Feb 22 08:19 PM
Wilson Mark AndrewChief Legal OfficerFeb 20 '24Sale0.687,6065,172236,674Feb 22 08:17 PM
ROBIN HOWARD WPresident & CEONov 17 '23Sale0.4919,8779,740899,922Nov 20 08:58 PM
Zalevsky JonathanChief R&D OfficerNov 17 '23Sale0.499,6464,727274,039Nov 20 09:02 PM
Wilson Mark AndrewChief Legal OfficerNov 17 '23Sale0.497,1793,518243,780Nov 20 09:00 PM
Curet MyriamDirectorSep 18 '23Sale0.694,3593,00827,418Sep 20 08:09 PM
Ajer Jeffrey RobertDirectorSep 18 '23Sale0.694,3593,00834,153Sep 20 08:06 PM
ROBIN HOWARD WPresident & CEOAug 16 '23Sale0.7819,99815,598919,799Aug 17 08:06 PM
Zalevsky JonathanChief R&D OfficerAug 16 '23Sale0.789,7037,568283,685Aug 17 08:08 PM
Wilson Mark AndrewChief Legal OfficerAug 16 '23Sale0.787,2215,632250,959Aug 17 08:07 PM
WHITFIELD ROY ADirectorJun 14 '23Sale0.5730,00017,100216,250Jun 15 06:26 PM
ROBIN HOWARD WPresident & CEOMay 16 '23Sale0.7220,36114,660939,797May 17 08:27 PM
Zalevsky JonathanChief R&D OfficerMay 16 '23Sale0.729,7917,050293,388May 17 08:29 PM
Wilson Mark AndrewChief Legal OfficerMay 16 '23Sale0.727,5435,431257,680May 17 08:28 PM